文献速递角膜与眼表疾病

耐阿昔洛韦的1型单纯疱疹病毒性角膜炎:一个令人担忧且新出现的临床挑战

Acyclovir-Resistant Herpes Simplex Virus 1 Keratitis: A Concerning and Emerging Clinical Challenge.
PubMed 文献 · Am J Ophthalmol · 2022-01-14

这项多中心回顾性病例系列描述了18例由耐阿昔洛韦(ACVR)1型单纯疱疹病毒(HSV-1)引起的单纯疱疹性角膜炎(HSK)患者的临床与病毒学特征;耐药检测因足量预防下频繁复发或抑制治疗反应差而进行,耐药突变见于胸苷激酶或DNA聚合酶基因,免疫功能低下者诊断耐药前的复发次数显著低于免疫功能正常者。

要点

  • HSK患者足量抗病毒预防下仍复发或抑制治疗方案反应差时,应怀疑HSV-1对阿昔洛韦耐药。
  • 免疫功能低下和/或长期患病者可能尤其易发生耐药。
  • 耐药突变83%位于胸苷激酶基因、17%位于DNA聚合酶基因。

核心结论

  • HSK患者足量抗病毒预防下仍复发和/或对抑制性抗病毒方案反应差时,必须怀疑HSV-1对阿昔洛韦耐药。
  • 免疫功能低下和/或长期患病者可能尤其面临发生耐药的风险。

研究设计与样本

  • 多中心回顾性病例系列。
  • 通过测序HSV-1胸苷激酶(TK)和DNA聚合酶(DNA pol)基因确认HSV-1对阿昔洛韦(ACV)耐药。
  • 收集耐药诊断前后HSK发作次数、眼部表现(含HSK类型)、免疫状态、抗病毒治疗及HSV-1基因型耐药谱等数据。

主要发现

  • 共评估18例HSK患者(男13例、女5例,年龄66.8 ± 4.7岁),眼样本ACVR HSV-1阳性。
  • 因足量抗病毒预防(AVP)下频繁复发(n=13,72%)或抑制性抗病毒治疗反应差(n=5,28%)而进行基因型耐药检测。
  • 耐药突变位于TK基因(n=15,83%)或DNA pol基因(n=3,17%)。
  • 耐药诊断前病程29.8 ± 20.4年,15例(83%)HSK复发超过10次。
  • 从首次发作到诊断耐药期间的复发次数,免疫功能低下患者(n=6,33%)显著低于免疫功能正常患者(n=12,67%)(11.5 ± 4.9 vs 16.4 ± 1.9,P = .05)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To describe the clinical and virological profiles of patients with herpes simplex keratitis (HSK) caused by acyclovir-resistant (ACVR) strains of herpes simplex virus 1 (HSV-1). DESIGN: Multicenter retrospective case series. METHODS: HSV-1 resistance to ACV was confirmed using sequencing of genes encoding HSV-1 thymidine kinase (TK) and DNA polymerase (DNA pol). Data were collected on the number of HSK episodes before and after the diagnosis of resistance, ocular findings including the type of HSK, immune status of patients, antiviral treatments, and HSV-1 genotypic resistance profiles. RESULTS: This study evaluated 18 HSK patients (13 male and 5 female, aged 66.8 ± 4.7 years) with ACVR HSV-1-positive ocular samples. Genotypic resistance testing was performed because of frequent recurrences despite adequate antiviral prophylaxis (AVP) (n = 13, 72%), or poor response to suppressive antiviral therapy (n = 5, 28%). Resistance mutations were found in the TK (n = 15, 83%) or in the DNA pol gene (n = 3, 17%). Prior to the diagnosis of resistance, the duration of disease was 29.8 ± 20.4 years, with more than 10 HSK recurrences in 15 patients (83%). The number of recurrences between the first episode and the diagnosis of resistance was significantly lower in immunocompromised patients (n = 6, 33%) than in immunocompetent patients (n = 12; 67%) (11.5 ± 4.9 vs 16.4 ± 1.9, P = .05). CONCLUSION: HSV-1 resistance to ACV must be suspected in HSK patients with recurrences despite AVP and/or in cases that respond poorly to a suppressive antiviral regimen. Immunocompromised patients and/or those with longstanding disease may be particularly at risk for developing resistance.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Rousseau A, Pharm SB, Gueudry J, et al. Acyclovir-Resistant Herpes Simplex Virus 1 Keratitis: A Concerning and Emerging Clinical Challenge. Am J Ophthalmol. 2022. PMID: 35033543. doi:10.1016/j.ajo.2022.01.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。